参考文献/References:
[1] NORO R, KOBAYASHI K, USUKI J, et al. Bevacizumabplus chemotherapy in nonsquamous non-smallcell lung cancer patients with malignant pleural effusionuncontrolled by tube drainage or pleurodesis: A phase IIstudy North East Japan Study group trial NEJ013B[J].Thoracic Cancer, 2020, 11(7): 1876-1884.
[2] ?OCHOWSKI M, ?OCHOWSKA B, R?BOWSKI M,et al. Five-year survival analysis and prognostic factorsin patients operated on for non-small cell lung cancerwith N2 disease[J]. Journal of Thoracic Disease, 2018,10(6): 3180-3186.
[3] ROEPER J, FALK M, CHALARIS-RI?MANN A, etal. TP53 co-mutations in EGFR mutated patients in NSCLCstage IV: A strong predictive factor of ORR, PFSand OS in EGFR mt+ NSCLC[J]. Oncotarget, 2020,11(3): 250-264.
[4] LIANG Hengrui,LIU Zhichao,CAI Xiuyu, et al. PD-(L)1 inhibitors vs. chemotherapy vs. their combinationin front-line treatment for NSCLC: An indirect comparison[J]. International Journal of Cancer, 2019, 145(11):3011-3021.
[5] 尚可, 胡若洋. 贝伐珠单抗联合紫杉醇和卡铂治疗非小细胞肺癌的效果研究[J]. 现代医药卫生,2020,36(6):913-915.SHANG Ke, HU Ruoyang. Effect of Bevacizumabcombined with Paclitaxel and Carboplatin on non-smallcell lung cancer [J]. Journal of Modern Medicine &Health,2020,36(6):913-915.
[6] LIU Yujie, ZHU Guopei, GUAN Xiyin, et al. Comparisonof the NCI-CTCAE version 4.0 and version 3.0 inassessing chemoradiation-induced oral mucositis forlocally advanced nasopharyngeal carcinoma[J]. OralOncology,2012,48(6):554-559.
[7] SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics,2018[J]. CA-A Cancer Journal for Clinicians,2018, 68(1): 7-30.
[8] 曹毛毛， 陈万青.GLOBOCAN 2020 全球癌症统计数据解读[J]. 中国医学前沿杂志（电子版），2021，13(3):63-69.CAO Maomao, CHEN Wanqing. Interpretationon the global cancer statistics of GLOBOCAN2020[J]. Chinese Journal of the Frontiers of ModicalScience(Electronic Version), 2021,13(3):63-69.
[9] LEMA D A,JANKOWSKA-GAN E,SETHAKORN N,et al. Identification of PD1-mediated regulation of antitumorantigen response in patients with NSCLC using the trans vivo DTH assay[J]. Journal for Immunotherapyof Cancer, 2020, 8(1):e000152.
[10] IDERZORIG T, KELLEN J, OSUDE C, et al. Comparisonof EMT mediated tyrosine kinase inhibitorresistance in NSCLC [J]. Biochemical and BiophysicalResearch Communications, 2018, 496(2) : 770-777.
[11] SCHROCK A B,MADISON R,ROSENZWEIG M, etal. Patients with NSCLCs harboring internal inversionsor deletion rearrangements of the ALK gene have durableresponses to ALK kinase inhibitors[J]. Lung Cancer:Targets and Therapy, 2020, 2020(11) : 33-39.
[12] AL-SAMKARI H, LEIVA O, DAGOGO-JACK I, et al.Impact of ALK rearrangement on venous and arterialthrombotic risk in NSCLC[J]. Journal of Thoracic Oncology,2020, 15(9): 1497-1506.
[13] 中国非小细胞肺癌ALK 检测模式真实世界多中心研究专家组, 中华医学会病理学分会分子病理学组.中国非小细胞肺癌ALK 检测临床实践专家共识 [J].中华病理学杂志,2019,48 (12): 913-920.Experts from the RATICAL Study (ALK Testing inChinese Advanced Non-Small Cell Lung Cancer Patients:A National-Wide Multicenter Prospective RealWorld Data Study), Molecular Pathology Committeeof Chinese Society of Pathology. Expert consensus onclinical practice of ALK fusion detection in non-smallcell lung cancer in China [J]. Chinese Journal of Pathology,2019,48(12):913-920.
[14] JIN Linling, WANG Yanli, LI Si, et al. Novel PNPT1-ALK fusion variant exerted significant benefit to crizotinibin NSCLC[J]. Lung Cancer,2020,146(C):382-384.
[15] 张旭阳, 刘冬洁, 肖月, 等. 抗血管生成在治疗非小细胞肺癌中的应用效果评价[J]. 心理月刊,2020,15(7):171.ZHANG Xuyang, LIU Dongjie，XIAO Yue，et al. Theeffect of antiangiogenesis in the treatment of non-smallcell lung cancer [J]. Psychologies,,2020,15(7):171.
[16] 李雪峰, 金艺凤. 抗血管生成剂在治疗非小细胞肺癌中的作用[J]. 齐齐哈尔医学院学报，2020，41(1)：93-95.LI Xuefeng, JIN Yifeng. Application of antiangiogenicagents in the treatment of non-small cell lungcancer [J]. Journal of Qiqihar Medical University,2020,41(1):93-95.
[17] FOSSELLA F V, DE VORE R, KERR R N, et al. Randomizedphase III trial of docetaxel versus vinorelbineor ifosfamide in patients with advanced non-small-celllung cancer previously treated with platinum-containingchemotherapy regimens. The TAX 320 Non-SmallCell Lung Cancer Study Group[J]. Journal of ClinicalOncology, 2000, 18(12): 2354-2362.
[18] 赵格, 高琼, 余宗涛, 等. 肺癌患者血浆miR-3151表达水平与临床病理特征的相关性研究[J]. 现代检验医学杂志,2020,35(5):28-32.ZHAO Ge,GAO Qiong,YU Zongtao,et al. Study onthe correlation between the expression of miR-3151 inplasma and clinicopathological features in patients withlung cancer [J]. Journal of Modern Laboratory Medicine,2020,35(5):28-32.
[19] 高敏, 刘若男, 柯张延, 等.TAP，Hsp90α 联合肺癌肿瘤标志物对小细胞肺癌诊断价值[J]. 临床肺科杂志,2020,25(1):88-92.GAO Min, LIU Ruonan, KE Zhangyan, et al. Diagnosticvalue of TAP and Hsp90α combined with lung cancertumor markers in small cell lung cancer [J]. Journalof Clinical Pulmonary Medicine,2020,25(1):88-92.
[20] YANG Huisi, BAO Jing, HUO Danqun,et al. Au dopedpoly-thionine and poly-m-Cresol purple: Synthesis andtheir application in simultaneously electrochemicaldetection of two lung cancer markers CEA and CYFRA21-1[J]. Talanta, 2021, 224 : 121816.
[21] CHIU Nanfu, YANG Haotang.High-sensitivity detectionof the lung cancer biomarker CYFRA21-1 inserum samples using a carboxyl-MoS2 functional filmfor SPR-based immunosensors.[J]. Frontiers in Bioengineeringand Biotechnology, 2020, 8 : 234.
[22] 雷田.CEA,CYFRA21-1,SCC 和ProGRP 检测对肺癌的诊断价值分析[J]．数理医药学杂志, 2021, 34 (1):51-52.LEI Tian. Diagnostic value of CEA,CYFRA21-1 ,SCCand ProGRP in lung cancer [J]. Journal of MathematicalMedicine, 2021,34(1):51-52.
[23] 夏靖华, 李维妙, 王雪娇, 等.CyclinD1 与CyclinD3在非小细胞肺癌中的表达及意义[J]. 肿瘤学杂志,2016,22(8):615-621.XIA Jinghua,LI Weimiao,WANG Xuejiao,et al. Expressionsof CyclinD1 and CyclinD3 in non-small cell lungcancer patients and their significance [J]. Journal ofChinese Oncology,2016,22(8):615-621.
[24] 常晓嫒，朱云霞，韩晓，等．microRNA-24 通过下调CDK4 和CyclinD3 抑制胰岛β 细胞增殖[J]．南京医科大学学报（自然科学版）,2016,36(12):1413-1417.CHANG Xiaoyuan, ZHU Yunxia, HAN Xiao, et al.MicroRNA-24 inhibits islet β-cell proliferation bydecreasing CDK4 and CyclinD3 protein levels [J].Journal of Nanjing Medicial University（Natural Science）,2016,36(12):1413-1417.
[25] COBAIN E F, PAOLETTI C, SMERAGE J B, et al.Clinical applications of circulating tumor cells inbreast cancer[J]. Recent Results in Cancer Research.Fortschritte der Krebsforschung. Progres dans les Recherchessur le Cancer, 2020, 215: 147-160.
[26] RADHAKRISHNAN V，BANAVALI S， GUPTA S，et al. Excellent CBR and prolonged PFS in non-squamousNSCLC with oral CA-170, an inhibitor of VISTAand PD-L1[J]. Annals of Oncology, 2019, 30(Supl5) :v494.
[27] TAKEZAWA K, PIRAZZOLI V, ARCILA M E, et al.HER2 amplification: a potential mechanism of acquiredresistance to EGFR inhibition in EGFR-mutant lungcancers that lack the second-site EGFRT790M mutation[J]. Cancer Discovery, 2012, 2(10): 922-933.
相似文献/References:
[1]陈 相a,陶国华a,周 峰a,等.叉头框蛋白J2在非小细胞肺癌组织
和癌旁组织中的表达及临床意义[J].现代检验医学杂志,2016,31(03):95.[doi:10.3969/j.issn.1671-7414.2016.03.026]
CHEN Xianga,TAO Guo-huaa,ZHOU Fenga,et al.Expression and Its Clinical Significance of Forkhead Box J2
in Non-small Cell Lung Cancer Tissues and Paracancerous Tissues[J].Journal of Modern Laboratory Medicine,2016,31(04):95.[doi:10.3969/j.issn.1671-7414.2016.03.026]
[2]刘丽燕a,陈晓丹b,杨明夏c,等.外周血异常糖链糖蛋白检测对非小细胞肺癌患者治疗监测的意义[J].现代检验医学杂志,2017,32(01):103.[doi:10.3969/j.issn.1671-7414.2017.01.028]
LIU Li-yana,CHEN Xiao-danb,YANG Ming-xiac,et al.Significance of Tumor Abnormal Protein in Peripheral Blood
in the Therapeutic Monitoring of Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2017,32(04):103.[doi:10.3969/j.issn.1671-7414.2017.01.028]
[3]张永庆a,尚立群a,苗 毅a,等.表皮生长因子受体基因突变与非小细胞肺癌病理的相关性分析[J].现代检验医学杂志,2017,32(06):78.[doi:10.3969/j.issn.1671-7414.2017.06.001]
ZHANG Yong-qinga,SHANG Li-quna,MIAO Yia,et al.Analysis of the Correlation between Mutations of the Epidermal Growth
Factor Receptor Gene and Pathological of Non Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2017,32(04):78.[doi:10.3969/j.issn.1671-7414.2017.06.001]
[4]喻 晶,李运雷,刘晓翌.非小细胞肺癌患者不同类型样本中表皮生长因子受体基因突变的差异研究[J].现代检验医学杂志,2018,33(04):31.[doi:10.3969/j.issn.1671-7414.2018.04.008]
YU Jing,LI Yun-lei,LIU Xiao-yi.Detection of Epidermal Growth Factor Receptor Gene Mutation
in Different Sample Types of 238 Patients with Non-small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2018,33(04):31.[doi:10.3969/j.issn.1671-7414.2018.04.008]
[5]林文科,吴吉芳,郑志昂.非小细胞肺癌患者血清miR-141及miR-224的表达及其临床意义[J].现代检验医学杂志,2018,33(02):46.[doi:10.3969/j.issn.1671-7414.2018.02.001]
LIN Wen-ke,WU Ji-fang,ZHENG Zhi-ang.Expression of Serum miR-141 and miR-224 in Patients
with Non-Small Cell Lung Cancer and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2018,33(04):46.[doi:10.3969/j.issn.1671-7414.2018.02.001]
[6]邝美华,陈意珊,石亚玲.血小板与淋巴细胞比值对非小细胞肺癌预后评估的Meta分析[J].现代检验医学杂志,2018,33(03):112.[doi:10.3969/j.issn.1671-7414.2018.03.028]
KUANG Mei-hua,CHEN Yi-shan,SHI Ya-ling.Prognostic Value of Platelet to Lymphocyte Ratio
in Non-Small Cell Lung Cancer:a Meta-analysis[J].Journal of Modern Laboratory Medicine,2018,33(04):112.[doi:10.3969/j.issn.1671-7414.2018.03.028]
[7]苗留飞,杨 阳,余柏增,等.三代EGFR-TKI奥希替尼(AZD9291)耐药细胞系建立及耐药标志预测分析[J].现代检验医学杂志,2019,34(05):28.[doi:10.3969/j.issn.1671-7414.2019.05.008]
MIAO Liu-fei,YANG Yang,YU Bai-zeng,et al.Establishment of the Third Generation of EGFR-TKI Resistant CellLine
and Resistance Gene Signature[J].Journal of Modern Laboratory Medicine,2019,34(04):28.[doi:10.3969/j.issn.1671-7414.2019.05.008]